title: Biomarkers of plaque instability.
abstract: Atherosclerosis is the proximate cause of arterial thrombosis, leading to acute occlusive cardiovascular syndromes. Thrombosis in atherosclerosis usually results from rupture of the fibrous cap of atherosclerotic plaques with a smaller proportion resulting from superficial endothelial erosion. Ruptured plaques are often associated with intimal and adventitial inflammation, increased size of lipid-rich necrotic core with thinned out collagen-depleted fibrous cap, outward remodeling, increased plaque neovascularity, intraplaque hemorrhage, and microcalcification. By inference, non-ruptured plaques with similar compositional features are considered to be at risk for rupture and hence are labeled vulnerable plaques or high-risk plaques. Identification of vulnerable plaques may help in predicting the risk of acute occlusive syndromes and may also allow targeting for aggressive systemic and possibly local therapies. Plaque rupture is believed to result from extracellular matrix (which comprises the protective fibrous cap) dysregulation due to excessive proteolysis in the context of diminished matrix synthesis. Inflammation is believed to play a key role by providing matrix-degrading metalloproteinases and also by inducing death of matrix-synthesizing smooth muscle cells. Systemic markers of inflammation are thus the most logical forms of potential biomarkers which may predict the presence of vulnerable or high-risk plaques. Several studies have suggested the potential prognostic value of a variety of systemic markers, but regrettably, their overall clinical predictive value is modestly incremental at best, especially for individual subjects compared to groups of patients. Nevertheless, continued investigation of reliable, cost-effective biomarkers that predict the presence of a high-risk plaque and future athero-thrombotic cardiovascular events with greater sensitivity and specificity is warranted.
authors.affiliation: Division of Cardiology, Atherosclerosis Prevention and Treatment Center, Oppenheimer Atherosclerosis Research Center, Cedars Sinai Heart Institute, 127 South San Vicente Blvd: Suite A3307, Los Angeles, CA, 90048, USA, shahp@cshs.org.
authors.forename: P K
authors.initials: PK
authors.lastname: Shah
mesh_terms: D016824:Antigens, Human Platelet / Q000378:metabolism; D016632:Apolipoprotein A-I / Q000378:metabolism; D050197:Atherosclerosis / Q000097:blood* / Q000378:metabolism / Q000503:physiopathology; D015415:Biomarkers / Q000097:blood / Q000378:metabolism*; D002097:C-Reactive Protein / Q000378:metabolism; D003324:Coronary Artery Disease / Q000097:blood / Q000378:metabolism* / Q000503:physiopathology; D003328:Coronary Thrombosis / Q000097:blood / Q000378:metabolism* / Q000503:physiopathology; D003362:Cost-Benefit Analysis; D005109:Extracellular Matrix / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000378:metabolism*; D020382:Interleukin-18 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008744:Methylamines / Q000378:metabolism; D009195:Peroxidase / Q000378:metabolism; D058226:Plaque, Atherosclerotic / Q000378:metabolism*; D011266:Pregnancy-Associated Plasma Protein-A / Q000378:metabolism; D011379:Prognosis
chemical_list: D016824:Antigens, Human Platelet; D016632:Apolipoprotein A-I; D015415:Biomarkers; D020382:Interleukin-18; D015850:Interleukin-6; D008744:Methylamines; C083451:human platelet antigen 1b; D002097:C-Reactive Protein; D009195:Peroxidase; D011266:Pregnancy-Associated Plasma Protein-A; C579283:PAPPA protein, human; C005855:trimethyloxamine